6 August 2026

Osteopore expands orthopaedic product segment into Middle East

Highlights

- **Osteopore is pleased to announce that it has signed a 3-year distribution agreement with Al-Umnia Medical LLC (Al-Umnia) for its orthopaedic products in the following 5 countries in the Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar and Bahrain.**
- **Founded in Dubai (2009) as a 4-member team, Al-Umnia is focused on building partnerships with leading international medical technology suppliers in the Gulf Cooperation Council (GCC) region. Today, Al-Umnia is a 70+ strong, multi-department organisation.**
- **Osteopore and Al-Umnia shall now proceed with product registration in the 5 countries, according to each country's requirements and practice.**
- **The GCC orthopaedic devices market was valued at approximately USD 897.5 million in 2025 and is forecast to reach USD 1.55 billion by 2034 (6.04% CAGR), with the UAE the largest single market at 31.5% share. Synthetic bone substitutes form a distinct segment within this market[1].**

Australian-Singaporean regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce that it has signed a distribution agreement with Al-Umnia Medical LLC (Al-Umnia) for its orthopaedic products in the following 5 countries: Saudi Arabia, United Arab Emirates, Oman, Qatar and Bahrain.

[1] IMARC Group, GCC Orthopaedic Devices Market Report, 2026-2034

Founded in Dubai (2009) as a 4-member team, Al-Umnia is focused on building partnerships with leading international medical technology suppliers in the Gulf Cooperation Council (GCC) region. Today, Al-Umnia is a 70+ strong, multi-department organisation, with an annual sales turnover of more than EUR 10m since 2023.

Osteopore and Al-Umnia shall now proceed with product registration in these 5 countries, according to each country's requirements and practice.

The Middle East represents one of the most compelling growth opportunities in orthopaedic bone regeneration globally. Contrary to the declining global trend, the age-standardised incidence of lower-extremity fractures across the Middle East and North Africa rose 4.57% between 1990 and 2019, with Saudi Arabia recording the highest age-standardised fracture incidence in the entire region at 2,010.56 per 100,000 population[2].

This pattern is driven substantially by road trauma in a young, working-age population — Saudi Arabia recorded 63,737 road traffic accidents between 2016 and 2020, concentrated in Riyadh and Makkah[3]. The opportunity extends beyond trauma – approximately 80% of bone sarcomas arise in the femur, tibia, humerus and pelvis[4].

The GCC orthopaedic devices market was valued at approximately USD 897.5 million in 2025 and is forecast to reach USD 1.55 billion by 2034 (6.04% CAGR), with the UAE the largest single market at 31.5% share. Synthetic bone substitutes form a distinct segment within this market[1].

---

[2] doi: 10.2106/JBJS.23.00489

[3] doi: 10.25122/jml-2023-0316

[4] doi: 10.1016/j.jbo.2020.100319

Key terms of the agreement:

- Product segment: orthopaedic bone reconstruction
- Period: 3 year agreement with the option of another year of extension
- Countries: Saudi Arabia, United Arab Emirates, Oman, Qatar and Bahrain
- Termination clause: related to non-performance of sales purchase targets

Commenting on the commercial expansion of orthopaedics into the Middle East, CEO Dr Yujing Lim, said:

"Our orthopaedics bone reconstruction product line is now progressing to the next phase of commercialisation – beyond South East Asia to the Middle East.

"We are delighted to partner with Al-Umnia, who have a strong presence in the region with an organisation structure focused on clinical education, training, and support", said Dr Lim.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Mark Leong
Executive Chairman
Osteopore Limited
E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.